POS1440 HEMATOLOGICAL MALIGNANCIES AND ANTI-TNF IN INFLAMMATORY ARTHRITIS: THE REAL LIFE DATA FROM THE HUR-BIO REGISTRY
$ 16.00
In stock
Product Description
Risk of Malignancies Across Biologic Classes in Rheumatoid Arthritis: Analysis of a National Claim Database - ACR Meeting Abstracts
Bayram FARISOĞULLARI, Rheumatologist, Hacettepe University, Ankara, Department of Rheumatology
TNF biology, pathogenic mechanisms and emerging therapeutic strategies
Death by TNF: a road to inflammation
Bayram FARISOĞULLARI, Rheumatologist, Hacettepe University, Ankara, Department of Rheumatology
Cell-centred meta-analysis reveals baseline predictors of anti-TNFα non-response in biopsy and blood of patients with IBD
Anti-TNF-α agents in the treatment of immune-mediated inflammatory diseases: mechanisms of action and pitfalls
Emine DURAN, Fellow, Hacettepe University, Ankara, Department of Rheumatology
Hematologic Malignancy Risk in Inflammatory Arthritis Patients Treated with TNF Inhibitors: The Real-Life Data from the HUR-BIO Registry
PDF) Hematologic Malignancy Risk in Inflammatory Arthritis Patients Treated with TNF Inhibitors: The Real-Life Data from the HUR-BIO Registry
IJMS, Free Full-Text
